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Abstract
Background: We assessed the incidence of micro-metastases at surgical margins (SM) and pelvic
lymph nodes (LN) in patients submitted to radical retropubic prostatectomy (RP) after neoadjuvant
therapy (NT) or to RP alone. We compared traditional staging to molecular detection of PSA using
Taqman-based quantitative real-time PCR (qrt-PCR) never used before for this purpose.
Methods: 29 patients were assigned to NT plus RP (arm A) or RP alone (arm B). Pelvic LN were
dissected for qrt-PCR analysis, together with right and left lateral SM.
Results: 64,3% patients of arm B and 26.6% of arm A had evidence of PSA mRNA expression in
LN and/or SM. 17,2% patients, all of arm B, had biochemical recurrence.
Conclusions: Qrt-PCR may be more sensitive, compared to conventional histology, in identifying
presence of viable prostate carcinoma cells in SM and LN. Gene expression of PSA in surgical
periprostatic samples might be considered as a novel and reliable indicator of minimal residual
disease after NT.
Background
Prostatic carcinoma has an unpredictable clinical behav-
ior. This cancer is widespread in males with 1/5 of men
being affected throughout life. Every year 209,900 new
cases are diagnosed in the USA. However, only 20% of
them will lead to demise of the patient with an approxi-
mately 9-year reduction in expected survival. Thus, pros-
tate cancer remains the second cause of oncologic death in
males in Europe and in the USA [1].
Because of patient-to-patient heterogeneity in the clinical
behavior of this disease, prognostic markers that may help
tailor therapeutic strategies to individual clinical situa-
tions are continuously re-assessed. This frequent reassess-
ment leads to modifications of clinical criteria utilized for
the selection of therapeutic strategies which, in turn, make
difficult the comparison and interpretation of clinical
results among different therapeutic strategies.
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In particular, there is a well known discrepancy between
post-surgical progression after radical prostatectomy and
pathological staging. Often local or systemic progression
is observed in patients theoretically at low risk such those
staged as pT2N0 [2,3]. Thus, current pathological staging
cannot comprehensively evaluate neoplasm extent,
aggressiveness and risk of progression. Clinical recurrence
after surgical excision could be ascribed to microscopic
nodal metastases and/or micro-invasion at the margins of
resection missed by pathological staging. To complement
pathological staging, new diagnostic and prognostic
markers (SHBG [4], p53, bcl2 Human Callicrein-2, PSMA,
and so forth) are under evaluation. Reverse Tanscriptase
Polymerase Chain Reaction (RT-PCR) for determination
of prostate-specific antigen (PSA) can detect a single pros-
tate cancer cell in a tissue sample [5,6]. The high sensitiv-
ity of this technique may increase the accuracy of staging
in low tumor burden cases and, consequently, be a more
appropriate molecular marker for the determination of
the effectiveness of a neoadjuvant therapy such as Maxi-
mum Androgenic Blockage (MAB) before radical prostate-
ctomy. In fact, this therapeutic approach is believed to
induce a down staging of the disease. However, it has been
questioned whether pre-operative hormonal blockade
may introduce a bias in pathological staging due to the
iatrogenically induced tissue changes[3,7].
In this study, we assessed the incidence of micro-metas-
tases at surgical margins and pelvic lymph nodes in
patients submitted to radical prostatectomy after neoadju-
vant MAB or to radical prostatectomy alone. We com-
pared traditional histopathological staging to molecular
detection of PSA using Taqman-based quantitative real-
time PCR (qrt-PCR) never used before for this purpose.
Materials and methods
Study design and patients' population
This is a report about an open randomized monocentric
pilot study with parallel arms, approved by the Ethics
Committee of our Institution. Thirty-three < 80 year-old
patients were accrued from July 2000 to June 2002. All
were clinically staged as having a previously untreated,
histologically confirmed T1-T2 prostate cancer. Patients
were randomly assigned to neoadjuvant hormonal ther-
apy plus radical prostatectomy (arm A) or radical prosta-
tectomy alone (arm B). Clinical and pathological stages
were determined according to the 1997 American Joint
Committee-International Union Against Cancer TNM Sys-
tem. Pre-treatment evaluation included clinical history,
digital rectal examination, serum PSA determination
using Hybritech technique, routine blood tests, trans-rec-
tal ultrasound, confirmation of out-side diagnosis,
abdominal computerized tomography and radioisotope
bone scan.
Patients in both arms underwent pelvic lymphadenec-
tomy and radical retro-pubic prostatectomy 55 to 70 days
from randomization. Neoadjuvant therapy consisted of:
Nilutamide 150 mg daily until surgery and subcutaneous
administration of Buserelin Depot 9,9 mg on the day of
randomization.
Surgical procedure
All patients underwent radical retro-pubic bladder neck
sparing prostatectomy with or without nerve sparing.
Bilateral pelvic (iliac and obturator) node dissection was
consistently performed and one right and one left node
were taken proximal to the iliac bifurcation, and preserved
in liquid nitrogen for subsequent qrt-PCR analysis. In
addition, the right and left lateral margins of resection
were submitted for pathological evaluation after dissec-
tion of a small wedge for cryostatic preservation (at least
0,5 cm of lenght). In all cases surgeons and pathologists
have checked the integrity of prostatic capsule in order to
be sure that these strips had been removed outside the
capsule (non containig prostatic tissue).
Pathological staging and molecular analysis
Pathological staging was traditionally assessed by immu-
nohistochemistry. In addition, the expression of the
tumor associated antigen PSA was quantified by means of
qrt-PCR in surgical margins and lymph nodes.
Tissue biopsies were immediately stored in liquid nitro-
gen until use. Once thawed, samples were minced with a
mechanical shredder. Total RNA was then isolated using
RNeasy Mini kits (Qiagen, Santa Clarita, CA) following
manufacturer's guidelines. One µg of total RNA was
reverse transcribed into cDNA using 1 µl of oligo-dT prim-
ers (1 µg/µl, GibcoBRL), 5 µl first strand buffer (Gibco-
BRL), 2 µl 0.1 M DTT, 2 µl magnesium sulfate
(GibcoBRL), 1 µl of 10 mM dNTP and 1 µl Superscript-II
(SS-II, GibcoBRL). The reaction mixture was heated to
65°C for 10 minutes before adding SS-II, then synthesis
was continued with 1 hour at 42°C. cDNA was stored at -
20°C until use.
The expression of PSA and of a housekeeping gene (i.e., β-
actin) was assessed by qrt-PCR as performed by the ABI
Prism 7700 Sequence Detection System (Perkin Elmer,
Foster City, CA) [8,9]. Probes and primers (See Table 1)
were designed to span intron-exon junctions in order to
avoid genomic DNA amplification.
To generate a standard curve for each gene, 1 µl of cDNA
obtained from normal prostate was added to the follow-
ing reagents: 1 µl Taqman primers (10 µM, Perkin Elmer),
5 µl 10 × PCR buffer (Perkin Elmer), 11 ml MgCl2 (25
mM), 1 ml dNPT (10 mM) and 0.5 µl AmpliTaq Gold
(Perkin Elmer) in a final volume of 50 µl. The thermalJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/13
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cycler conditions for this PCR reaction were as follows:
after 10 minutes at 95°C, 15 seconds at 95°C followed by
1 minute at 60°C were repeated 40 times. The equation
describing the standard curves was used to extrapolate the
absolute copy number of PSA and β-actin. Quantitative
real time PCR of sample cDNA and standard amplified
cDNA was conducted in a 25 µl final volume mixture con-
taining primers, probe and 1 × Taqman Master Mix (Per-
kin Elmer) at optimized concentrations (probe: 200 nM,
primers: 400 nM). The TaqMan ABI Prism 7700 Sequence
Detection System allows running 96 samples at a time.
Thermal cycler parameters included 2 minutes at 50°C,
10 minutes at 95°C and 40 cycles involving denaturation
at 95°C for 15 seconds and annealing/extension at 60°C
for 1 minute. To ensure that probes and primers in use did
not amplify genomic DNA, we extracted genomic DNA
from a normal prostate biopsy and tested it with the Taq-
man primers. Given the small size of the amplicons (<100
bp), a FluorImager 595 (Molecolar Dynamics, Sunnydale,
CA) scanning system was used to detect the fluorescence
of the Vistra Green fluorescent intercalator, which was
adopted instead of ethidium bromide to visualize the
bands of the agarose gel after electrophoresis. An Argon
laser for excitation (488 nm) and an emission band-pass
filter 530 DF30 were applied.
For qrt-PCR purposes, probes were labeled with a fluores-
cent reporter dye at the 5'-end (6-carboxyfluorescein, 6-
FAM; emission λmax = 518 nm) and a quencher dye at the
3'-end (6-carboxytetramethylrhodamine, TAMRA; emis-
sion λmax = 582 nm). Probe and primers were designed to
obtain amplicons less then 100 bp in length in order to
enhance PCR efficiency. Furthermore, they were designed
to span an intro-exon junction in order to avoid genomic
DNA amplification. Since both the amount of total RNA
added to each reverse transcription reaction tube (based
on waive length absorbance) and its quality (i.e. degrada-
tion) are not reliable parameters as measures of starting
material, transcripts of a housekeeping gene were quanti-
fied as endogenous control. Beta-actin (β-actin) is one of
the most used aspecific housekeeping genes, but accord-
ing to the experimental conditions, other internal refer-
ences can be adopted (e.g. leukocyte markers). For each
experimental sample the value of both the target and the
housekeeping gene are extrapolated from the respective
standard curve. The target value is then divided by the
endogenous reference value to obtain a normalized target
value independent from the starting material amount. The
results were reported as number of PSA copies per
100,000 β-actin copies.
Follow up
Patients were seen for follow up 50 days after surgery and
every 3 months thereafter during the first year, every 6
months during the subsequent four years and then annu-
ally. At each visit serum PSA was performed. Imaging
studies or biopsies were performed as appropriate.
Statistical analysis
Statistical analysis was performed on 29 valuable patients
randomized and included in the study. For each patients
(arm A or B) qrt-PCR results from lateral surgical margins
and pelvic nodes were analyzed. Statistical evaluation and
data elaboration was made using SAS's software (Statisti-
cal Analysis System). Continuity Adjust Chi-Squared test
was used to assess differences in qrt-PCR results between
arm A and B. P values of = 0.05 were considered statisti-
cally significant. P-values are given as two-tailed.
Results
A total of 33 eligible patients were enrolled and rand-
omized. Of these, 29 were evaluated for analysis. Four
patients did not complete the protocol. One dropped out
for noncompliance, one for pneumonia, one for allergy to
Nilutamide and one because the sample was inadequate
to perform qrt-PCR analysis. Of 29 patients, 15 (51,7%)
underwent neo-adjuvant MAB treatment (arm A) and 14
(48,3%) received prostatectomy alone (arm B). Five of the
29 patients (17,2%) experienced biochemical recurrence
after a mean follow-up of 19 months, all of these patients
belonged to arm B.
Pathological and molecular findings
In the neo-adjuvant arm A 5/15 (33,3%) patients were
staged as pT2a-G2. All of them were negative at qrt-PCR
analysis for PSA expression. One of 15 patients (6,6%)
was staged as pT2a-G3 and resulted positive at qrt-PCR.
Four of the 15 patients (26,8%) were pT2b-G2: 2 resulted
negative and 2 positive at qrt-PCR. Five of the 15 (33,3%)
patients were pT3b-G2 and 4 resulted negative and 1 pos-
itive to qrt-PCR (See Table 2).
The ratio of PSA mRNA expressing patients according to
qrt-PCR in arm A was of 26,6% (4/15).
Table 1: Probes and primers used
Probe Forward Reverse
PSA 6FAM-CAGCATTGAACCAGAGGAGTTCTTGACCC-TAMRA 5'-GACCACCTGCTACGCCTCA-3' 5'-GGAGGTCCACACTGAAGTTTC-3'
β-actin 6FAM-TCAAGATCATTGCTCCTCCTGAGAGCGC-TAMRA 5'-GGCACCCAGCACAATGAAG-3' 5'-GCCGATCCACACGGAGTACT-3'Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/13
Page 4 of 7
(page number not for citation purposes)
In arm B, 4/14 (28,6%) patients were pT2a-G2 of this 3
negative and one positive at qrt-PCR analysis; 6/14
(42,8%) patients were pT2b-G2, one negative and 5 posi-
tive to qrt-PCR; 4/14 (28,6%) patients were pT3b-G2, one
negative and 3 positive for PSA expression in periprostatic
tissues (See Table 3)
Overall 64,3% (9/14) of the patients had evidence of PSA
mRNA expression in arm B, while 26.6% (4/15) resulted
molecularly positive in arm A (Fisher exact test = 0.04).
Pathological and molecular finding of the patients who
had biochemical recurrence are reported in Table 4.
Statistical analysis
Analysis was performed on patients from arm A or B
whether they had or had not cumulative evidence of PSA
mRNA expression by qrt-PCR in lymph nodes and/or lat-
eral surgical margins. Nine of 14 (64,29%) patients
expressed PSA in arm B and four of 15 (26,67%) in arm A
(See Table 5).
Continuity Adjust Chi-Square (a Chi-Square modified for
not continuous variable) was calculated and resulted in
0.0965, this value trend to statistical significance. This
results suggests a difference between arm A and B,
although not statistically significant (See Table 6). In
Table 7 are reported assessment of Relative Risk and his
confidence limits. Value founded show the risk to be pos-
itive if not treated with neoadjuvant therapy respect to
treated arm; the risk to have positive surgical margins or
nodes to qrt-PCR is 2,41 higher in not treated patients
(arm B).
Discussion
Radical Prostatectomy is widely performed in early pros-
tate cancer and it may lead to cure as long as the cancer is
confined to the prostate and all neoplastic cells are
removed [10].
Clinical staging is inaccurate and a significative number of
patients with prostate cancer defined as cT1-2 are found to
have positive surgical margins. This in turn is associated
with increased chances of cancer recurrence and
Table 2: Pathological and qrt-PCR data of arm A patients.
N° pts % Path. staging qrt-PCR (-) qrt-PCR (+)
5 33,3 T2a-G2 5 0
1 6,6 T2a-G3 0 1 (surgical margins)
4 26,8 T2b-G2 2 2 (surgical margins)
5 33,3 T3b-G2 4 1 (surgical margins)
Table 3: Pathological and qrt-PCR data of arm B patients.
N° pts % Path. staging qrt-PCR (-) qrt-PCR (+)
4 28,6 T2a-G2 3 1 (surgical margins)
6 42,8 T2b-G2 1 5 (2 pts positive nodes)
4 28,6 T3b-G2 1 3 (2 pts positive nodes)
Table 4: Disease recurrence
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progression within 5 years from the surgical resection of
the primary tumor [11].
Neoadjuvant hormonal therapy may reduce the rate of
margin positiveness, therefore, decreasing the chance of
observing a local recurrence after Radical Prostatectomy
[12]. However, it has been suggested that after neoadju-
vant hormonal therapy residual foci of atrophic glands
can be difficult to identify with hematoxylin and eosin
staining, increasing the possibility that pT may be under
staged [13-15].
Clinical randomized studies adopting neoadjuvant ther-
apy before radical prostatectomy have demonstrated a
reduction of the risk of leaving positive surgical margins
in pT1-2 patients at the time of the surgical procedure and
this reduced risk is proportional to the length of
treatment.
The timing and schedule of administration of neoadju-
vant therapies are still not well defined [7]. Several groups
investigated the use of hormonal therapy before radical
prostatectomy. The primary end point of these studies was
to assess whether neoadjuvant therapy can increase
overall survival. Indeed, there is no published evidence
that patients undergoing MAB before radical prostatec-
tomy have a clear benefit [16]. At the same time there is
no compelling evidence that neoadjuvant therapy is not
effective [17].
The use of PCR methods for determination of PSA gene
expression in surgical periprostatic samples has suggested
new staging strategies based on higher sensitivity. It is
now possible to obtain information about presence of
prostatic tissue in extra glandular structures with more
sensitivity compared with conventional histology [5,6].
Traditional methods to study protein or gene expression
in tumor biopsies include mainly immunohistochemistry
and polymerase chain reaction (PCR). These techniques
are not quantitative and allow only a semi quantitative
evaluation based on the subjective judgment of the
observer, which makes the comparison between samples
inaccurate (unreliable). Flow cytometry is highly reliable
Table 5: Treatment Response
Negative Positive Total
Arm B 5 9 14
% 17.24 31.03 48.28
Row Pct 35.71 64.29
Col Pct 31.25 69.23
Arm A 11 4 15
% 37.93 13.79 51.72
Row Pct 73.33 26.67
Col Pct 68.75 30.77
Total 16 13 29
55.17 44.83 100.00
Table 6: Statistics for Table of Treatment by Response
Statistic used DF Value Prob
Continuity Adj. Chi-Square 1 2.7621 0.0965
Table 7: Estimates of the Relative Risk
Type of Study Value 95% Confidence Limits
Cohort 2.4107 0.9554
Sample Size = 29Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/13
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to determine the levels of expression of a given antigen.
However, it requires tissue desegregation procedures,
which can damage cell surface antigens, and can not be
performed in case of hypo cellular specimens. To measure
of the amount of gene expression several molecular meth-
ods have been described such as competitive PCR and
SAGE. These techniques are cumbersome, time consum-
ing and require multiple manipulations of the samples,
increasing the risk of carrying over contamination. Quan-
titative real-time PCR (qrtPCR) allows a highly sensitive
measurement of the transcriptional levels of the gene of
interest in a few hours with minimal handling of the sam-
ples. In addition, qrt-PCR is stringently sequence depend-
ent because of the labelled probe. Therefore, it yields
indirect sequence confirmation that the amplified prod-
uct is the gene of interest. Finally, the utilization of intro-
exon junction spanning probes avoids mis-calculation of
gene level expression due to genomic DNA contamina-
tion. This technique has been mainly used for viral load
measurement [18], but recently it has been employed for
eukaryotic studies and in particular analysis of human
mRNA expression in various clinical and therapeutic con-
ditions [19]. In this study, we adopted qrt-PCR for the sen-
sitive identification of PSA mRNA level in areas where it
should not be present such as positive surgical margins
and/or draining lymph nodes.
Conclusions
In our experience, neoadjuvant therapy for 3 months
before surgical intervention appears to affect disease stag-
ing. In fact, according to qrt-PCR results, the rate of lymph
nodes and/or surgical margins in which PSA mRNA could
be detected was significantly lower (26.6%) in arm A
(MAB plus surgery) as compared to that found in arm B
(surgery alone) (64,3%). All the 5 patients that experi-
enced biochemical evidence of recurrence (17,2%)
belonged to arm B.
Although, PSA mRNA was detected by qrt-PCR in 60% of
patients who experienced biochemical recurrence six of
the remaining 8 patients in arm B had also detectable PSA
mRNA.
This finding suggests that identification of PSA mRNA
expression at the surgical margin or draining lymph-
nodes is more a marker of the ability of the neoadjuvant
therapy to sterilize the patient before surgical intervention
than an independent predictor of recurrence. In fact, the
most significant difference in PSA mRNA expression was
noted between the two randomization arms where in the
neo-adjuvant protocol only 4 of 15 patients were positive
while 9 of 14 were positive in the surgical treatment alone
arm (Fisher test p2 value = 0.02). Thus, qrt-PCR appears to
yield useful information about the effectiveness of a given
therapy and it may be more sensitive, compared to con-
ventional histology, in identifying presence of viable pros-
tate carcinoma cells in surgical resection margins and
draining lymph nodes. Finally, this study seems to con-
firm that neoadjuvant therapy with Nilutamide 150 mg +
Buserelin Depot for 3 months before surgical intervention
induces clinically relevant down staging, at least in the
short term. If these results were confirmed in a larger series
of patients, we believe that gene expression of PSA in sur-
gical periprostatic samples might be taken into considera-
tion as a novel and reliable indicator of minimal residual
disease after neoadjuvant therapies. In this case, the
molecular detection of cancer cells might represent an
indication to adjuvant treatments in order to sterilize
microscopic foci of tumor possibly responsible for local
recurrence.
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